Neuraxpharm pays US$650m for MS drug commercialisation
TG Therapeutics will receive US$140m upfront from German Neuraxpharm for Ex-US commercialisation rights of its deglycosylated anti-CD20 antibody ublituximab-xiiy.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1185 entries already.
Entries by Thomas Gabrielczyk
PureTech Health gets US$11.4m to advance LYT-300
/in News/by Thomas GabrielczykLSE-listed PureTech Health plc hat been granted p to US$11.4m from U.S. Department of Defense to advance LYT-300 to treat Fragile X-associated tremor/ataxia syndrome.
Mithra Pharmaceuticals SA in 17m licencing deal
/in News/by Thomas GabrielczykMithra and Searchlight Pharma have inked a licensing deal for Donesta commercialisation in Canada.
Bacterial-fungal consortium denitrifies wastewater by 100%
/in News/by Thomas GabrielczykA German-Chinese reasearch consortium has identified a highly active denitrifying microbial consortium that denitrifies wastewater by almost 100%.
NK cell therapy company NK:IO raises seed money
/in News/by Thomas GabrielczykBritish NK cell therapy specialist NK:IO Ltd has added a £1.2m seed investment led by Cancer Research Horizons, bringing total seed funding to £5.1m.
Alnylam in US$2.8bn biobucks deal with Roche
/in News/by Thomas GabrielczyksiRNA specialist Alnylam Pharmaceuticals Roche has received US$310m upfront from Swiss Roche AG for the ex-US commercialisation rights of zilebesiran, an new antihypertensive. T
Resistance blocker of immune checkpoint inhibitors gets patented
/in News/by Thomas GabrielczykThe EPO has granted a patent to Domain Therapeutics Phase I candidate DT-9081 designed to reverse PGE2-mediated immunosuppression used by tumours to bypass the immune system.
Lilly presents impressing results for Alzheimer’s drug donanemab
/in News/by Thomas GabrielczykEli Lilly’s Alzheimer’s drug donanemab has speedy removed amyloid plaques in a pivotal Phase III trail halting disease progression for one year in half of patients.
Biomethane fuel offers negative carbon footprint
/in News/by Thomas GabrielczykAlthough the EU Commission wants to abolish the internal combustion engine in individual transport through eMobility, biofuels are far from dead, according to a new study.
Carbios raises 141m to boost enzymatic PET recycling
/in News/by Thomas GabrielczykIn an oversubscribed capital increase, Carbios SAS has raised 141m, the largest on Euronext growth since 2015.